What’s Yet To Come From Insulin Pipeline

The insulin market is undergoing great change, with pricing pressures by payers in the US and a biosimilar long-acting insulin approved in Europe and headed for the US. Leading sponsors have prepared by developing new products that offer incremental improvements.